Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
24.93 ^CNY	+0.69%		-0.32%	-4.48%

Apr. 24	Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4%	MT

Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million.

December 13, 2023

Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million on December 14, 2023. As of June 30, 2023, Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. generated total assets of CNY 237.07 million and net assets of CNY 52.4 million. The transaction is approved by board of directors of Tianjin Lisheng Pharmaceutical Co.,Ltd.

Latest news about Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4%	Mar. 22	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Lisheng Pharmaceutical Buys 65% Stake in Qingchun Kangyuan Pharmaceutical for 137 Million Yuan; Shares Up 3%	Jan. 02	MT
Tianjin Arm Lisheng Pharmaceutical To Buy Chinese Medicine Firm Jiangxi Qingchun Kangyuan	Dec. 14	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million.	Dec. 13	CI
Tianjin Lisheng Pharma Setting Up Venture Capital Fund	Dec. 12	MT
Lisheng Pharmaceutical and Lisheng Investment Enter into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway	Dec. 11	CI
Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake	Nov. 10	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million.	23-09-10	CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps	23-08-24	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Lisheng Pharmaceutical Subscribes for 20 Million Yuan Wealth Management Product	23-08-02	MT
Lisheng Pharma to Receive 247.9 Million Yuan for Relocation	23-07-26	MT
Lisheng Pharmaceutical Eyes 247.9 Million Yuan from Potential Land Resumption Deal	23-07-26	MT
Tianjin Lisheng Pharma Gets Nod For Febuxostat Active Pharma Ingredient in China	23-06-15	MT
Lisheng Pharma Unit's Drug Passes Regulatory Evaluation	23-05-15	MT
Tianjin Lisheng Pharmaceutical's Q1 Attributable Profit Increases	23-04-26	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Lisheng Pharmaceutical's Audited 2022 Profit Marginally Higher Than Unaudited Results	23-03-23	MT
Tianjin Lisheng Pharmaceutical's 2022 Attributable Profit Falls 23.5%	23-02-27	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Lisheng Pharmaceutical's January-September Profit Increases 15%	22-10-26	MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.

Duration

Period

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.

More charts

Company Profile

Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.	-4.48%	634M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B